US Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) Forecasts 2022-2032

US Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) Forecasts 2022-2032

US Preimplantation Genetic Diagnosis Market is valued at approximately USD 23.62 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.40% over the forecast period 2024-2032. Preimplantation Genetic Diagnosis (PGD) is a sophisticated reproductive technology used with In Vitro Fertilization (IVF) to screen embryos for genetic conditions before implantation. This technique enhances the likelihood of a healthy baby for couples at risk of passing on genetic conditions. IVF involves hormone stimulation of the ovaries, egg retrieval, and fertilization in a lab. Embryos are cultured to the blastocyst stage, where cells are biopsied and assessed for genetic defects. Only healthy embryos are selected for uterine transfer, reducing the transmission of genetic disorders and improving IVF success rates. PGD raises ethical concerns about embryo selection and genetic confidentiality but is beneficial for couples with a family history of genetic issues, multiple miscarriages, or infertility due to genetic abnormalities. The US Preimplantation Genetic Diagnosis Market is growing due to advancements in genetic technologies, increasing awareness of genetic disorders, and the trend of delayed parenthood. Rising infertility rates and expanding applications of PGD for non-medical purposes further drive market growth.

The US Preimplantation Genetic Diagnosis (PGD) market is driven by the increasing prevalence of genetic disorders, prompting more couples to opt for PGD to avoid passing on hereditary conditions to their children. PGD's ability to provide genetic information about embryos before implantation is a crucial factor driving its adoption among couples undergoing fertility treatments, as it enhances the chances of a successful pregnancy. The rises trend of delayed parenthood, coupled with increasing awareness about fertility preservation, is expected to drive the demand for PGD services in the US market. However, the market faces certain restraints. The high cost associated with PGD procedures is a barrier for many couples seeking these services. Ethical and legal concerns surrounding the use of PGD, particularly regarding embryo selection for non-medical reasons, pose challenges to market growth. Furthermore, the lack of insurance coverage for PGD procedures in some cases limits its accessibility to a broader population.

Major market players included in this report are:
Illumina, Inc.
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
PerkinElmer, Inc.
CooperSurgical, Inc.
Natera, Inc
Invitae Corporation
F. Hoffmann-La Roche Ltd
Good Start Genetics, Inc
Laboratory Corporation of America Holdings

The detailed segments and sub-segments of the market are explained below:

By Test Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorders
HLA Typing
Gender selection
Others

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.